ATE454455T1 - Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung - Google Patents

Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung

Info

Publication number
ATE454455T1
ATE454455T1 AT06719694T AT06719694T ATE454455T1 AT E454455 T1 ATE454455 T1 AT E454455T1 AT 06719694 T AT06719694 T AT 06719694T AT 06719694 T AT06719694 T AT 06719694T AT E454455 T1 ATE454455 T1 AT E454455T1
Authority
AT
Austria
Prior art keywords
guiding
production
heterologous
polypeptides
sequences
Prior art date
Application number
AT06719694T
Other languages
English (en)
Inventor
Robert Halenbeck
Elizabeth Bosch
Thomas Linnemann
Ernestine Lee
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Application granted granted Critical
Publication of ATE454455T1 publication Critical patent/ATE454455T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06719694T 2005-01-27 2006-01-27 Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung ATE454455T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64701305P 2005-01-27 2005-01-27
PCT/US2006/002951 WO2006081430A2 (en) 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof

Publications (1)

Publication Number Publication Date
ATE454455T1 true ATE454455T1 (de) 2010-01-15

Family

ID=36741080

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06719694T ATE454455T1 (de) 2005-01-27 2006-01-27 Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung

Country Status (9)

Country Link
US (1) US20080286834A1 (de)
EP (1) EP1841874B1 (de)
JP (2) JP2008528033A (de)
AT (1) ATE454455T1 (de)
AU (1) AU2006207999A1 (de)
CA (1) CA2589895A1 (de)
DE (1) DE602006011574D1 (de)
DK (1) DK1841874T3 (de)
WO (1) WO2006081430A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083081A1 (de) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Zusammensetzungen und Verfahren zur Behandlung von Krankheiten mit FGFR-Fusionsproteinen
EP1937815B1 (de) 2005-09-13 2015-05-13 National Research Council of Canada Verfahren und zusammensetzungen zur modulation der tumorzellaktivität
US9060961B2 (en) * 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
WO2009056330A1 (en) * 2007-10-31 2009-05-07 Eth Zurich Soluble truncated apom proteins and medical uses thereof
BRPI0909221A2 (pt) * 2008-03-25 2015-08-11 Amarantus Therapeutics Inc Desordens neurodegenerativas
FR2933773B1 (fr) * 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
BRPI0916904A2 (pt) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
WO2010075194A1 (en) * 2008-12-22 2010-07-01 St. Jude Children's Research Hospital Prokaryotic expression of soluble, active dkk
JP2010183885A (ja) * 2009-02-13 2010-08-26 Kobe Univ タンパク質の製造方法およびそれに用いる発現ベクター
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
PT2504363T (pt) 2009-11-24 2019-08-02 Nat Res Council Canada Anticorpos anticlusterina e fragmentos de ligação ao antigénio e a sua utilização para reduzir o volume de um tumor
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
MX355418B (es) 2010-05-04 2018-04-18 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
US8431532B2 (en) 2010-06-28 2013-04-30 Five Prime Therepeutics, Inc. FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same
EP2444495A1 (de) * 2010-10-20 2012-04-25 Algenics Sekretion rekombinanter Polypeptide im extrazellularen Medium eines Diatoms
NZ610487A (en) 2010-11-15 2015-03-27 Five Prime Therapeutics Inc Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
AU2012205384B2 (en) 2011-01-14 2015-09-10 Five Prime Therapeutics, Inc. IL-27 antagonists for treating inflammatory diseases
HK1202240A1 (en) 2011-11-14 2015-09-25 戊瑞治疗有限公司 Methods of treating cancer
MX2014010164A (es) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
JP2015517490A (ja) 2012-05-11 2015-06-22 ファイブ プライム セラピューティックス インコーポレイテッド コロニー刺激因子1受容体(csf1r)を結合させる抗体を用いて状態を治療する方法
BR112014030677A2 (pt) 2012-06-08 2022-07-19 Shire Human Genetic Therapies distribuição pulmonar de mrna para células-alvo não-pulmonares
SG10201906328RA (en) 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2014089486A1 (en) 2012-12-07 2014-06-12 Shire Human Genetic Therapies, Inc. Lipidic nanoparticles for mrna delivering
US20160184458A1 (en) 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
PH12019501393B1 (en) 2013-08-01 2022-09-07 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
KR20230086809A (ko) 2014-06-23 2023-06-15 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체 (csf1r)에 결합하는 항체를 이용하여 병태를 치료하는 방법
BR112017008914A2 (pt) 2014-10-29 2018-01-16 Five Prime Therapeutics, Inc. método para tratar câncer, composição e uso da composição
KR20170096187A (ko) 2014-12-22 2017-08-23 파이브 프라임 테라퓨틱스, 인크. Pvns를 치료하기 위한 항-csf1r 항체
KR20170129902A (ko) 2015-03-23 2017-11-27 조운스 테라퓨틱스, 인크. Icos에 대한 항체
CN107709365A (zh) 2015-04-13 2018-02-16 戊瑞治疗有限公司 癌症组合疗法
KR20180066236A (ko) 2015-10-22 2018-06-18 조운스 테라퓨틱스, 인크. Icos 발현을 계측하기 위한 유전자 특질
CN115975044A (zh) 2016-04-25 2023-04-18 戊瑞治疗有限公司 用于治疗病理性肌肉损失和虚弱的nope
HRP20211703T1 (hr) 2016-11-02 2022-02-04 Jounce Therapeutics, Inc. Protutijela protiv pd-1 i njihova upotreba
WO2018144097A1 (en) 2016-11-04 2018-08-09 Akeagen Llc Genetically modified non-human animals and methods for producing heavy chain-only antibodies
TWI685351B (zh) * 2016-12-29 2020-02-21 財團法人生物技術開發中心 延長蛋白質藥物體內半衰期的激肽原-1衍生胜肽
CA3057687A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
WO2018187191A1 (en) 2017-04-03 2018-10-11 Jounce Therapeutics, Inc Compositions and methods for the treatment of cancer
US11667686B2 (en) 2017-06-06 2023-06-06 Kindred Biosciences, Inc. Erythropoietin and analogs for veterinary use
JP7391868B2 (ja) 2017-12-22 2023-12-05 ジョウンセ セラピューティクス, インク. Lilrb2に対する抗体
CA3104530A1 (en) 2018-07-09 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
US20220112257A1 (en) * 2019-01-11 2022-04-14 Arbele Limited Mul tispecific prochemokine therapeutic proteins (park) and method of making and using thereof
CN121360236A (zh) 2019-03-01 2026-01-20 阿奇洛伊斯生物制药公司 在抗原特异性免疫细胞中调节cd160功能的方法及其用途
WO2021178001A1 (en) * 2020-03-05 2021-09-10 Curie Co. Inc. Methods for cell free protein expression of mature polypeptides derived from zymogens and proproteins
IL295023A (en) 2020-02-14 2022-09-01 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and their uses
US20230303695A1 (en) 2020-08-10 2023-09-28 Tengfei XIAO Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712114A (en) * 1995-06-06 1998-01-27 Basf Aktiengesellschaft Compositions for expression of proteins in host cells using a preprocollagen signal sequence
EP1105508B1 (de) * 1998-08-17 2002-09-04 Europäisches Laboratorium Für Molekularbiologie (Embl) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
US20080242603A1 (en) * 2004-02-20 2008-10-02 Yan Wang Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use
ATE540973T1 (de) * 2004-07-22 2012-01-15 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung

Also Published As

Publication number Publication date
DK1841874T3 (da) 2010-05-17
CA2589895A1 (en) 2006-08-03
WO2006081430A3 (en) 2007-04-05
JP2008528033A (ja) 2008-07-31
EP1841874A2 (de) 2007-10-10
US20080286834A1 (en) 2008-11-20
DE602006011574D1 (de) 2010-02-25
AU2006207999A1 (en) 2006-08-03
JP2009131268A (ja) 2009-06-18
WO2006081430A2 (en) 2006-08-03
WO2006081430A9 (en) 2006-11-30
EP1841874B1 (de) 2010-01-06

Similar Documents

Publication Publication Date Title
ATE454455T1 (de) Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
ATE521701T1 (de) Verbesserte konstrukte zur expression lysosomaler polypeptide
ATE478145T1 (de) Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
ATE448246T1 (de) Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
ATE424458T1 (de) Eg-vegf nukleinsäuren und polypeptide und verfahren zur deren verwendung
CY1112334T1 (el) Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων
KR100468977B1 (ko) 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
DK1169442T3 (da) Secernerede polypeptider og transmembran-polypeptider og nukleinsyrer, der koder for disse
ATE448312T1 (de) Leitsequenzen zur verwendung bei der produktion von proteinen
ATE483810T1 (de) Entkopplung von dna-propagierung und proteinexpression für phagen-display
WO2006053021A3 (en) Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby
MX345294B (es) Polipéptidos de unión quimérica de plantas para reconocimiento molecular universal.
ATE408016T1 (de) Verfahren zur herstellung und sekretion modifizierter peptide
EP4302824A3 (de) Zusammensetzungen und verfahren zur nukleinsäureexpression und proteinsekretion bei bakteroiden
EP3795586A3 (de) Herstellung von proteinen in labyrinthulomyceten
DK1366161T3 (da) Antagonist anti-PRO842-antistof
ATE319858T1 (de) Modulierte sekretierte alkalische phosphatase (seap) reporter gene und polypeptide
DE69926415D1 (de) Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren
DK1621619T3 (da) Secernerede polypeptider og transmembran-polypeptider og nukleinsyrer, der koder for disse
ATE332308T1 (de) Sekretiertes und transmembranes polypeptid und dafür kodierende nukleinsäure
ATE396201T1 (de) Ausgeschiedene und transmembranpolypeptide und dafür kodierende nukleinsäure
ATE447026T1 (de) Ausgeschiedene und transmembrane polypeptide und dafür kodierende nukleinsäure
ATE489463T1 (de) Polypeptid mit einer delta-5-fettsäure- desaturierungsaktivität, für das polypeptid codierendes polynukleotid und verwendung davon.
DK1251173T3 (da) Secernerede og transmembrane polypeptider og nucleinsyrer kodende for disse
DK1241184T3 (da) Humant synaptogyrin-lignende protein og nukleinsyrer kodende for dette

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties